On April 16, 2023 Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), reported preclinical data from the company’s portfolio of KIF18A inhibitors at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Orlando (Press release, Volastra Therapeutics, APR 16, 2023, View Source;utm_medium=rss&utm_campaign=preclinical-data-on-volastra-therapeutics-two-novel-and-differentiated-kif18a-inhibitors-presented-at-aacr-2023 [SID1234630122]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Volastra’s KIF18A portfolio consists of two clinical-stage highly differentiated, novel, first-in-class KIF18A inhibitors: recently in-licensed sovilnesib (formally AMG650) and internally-developed VLS-1488. Each will have poster presentations at the meeting.
"We are proud to have side-by-side posters on our two groundbreaking KIF18A inhibitors at AACR (Free AACR Whitepaper)," said Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra. "KIF18A is an exciting and novel target in oncology, and we see huge potential benefits for patients with our two drugs, each having distinct molecular properties."
Sovilnesib findings, presented in a poster entitled "Discovery and preclinical characterization of AMG650, a first-in-class inhibitor of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers" (#516), demonstrate robust anti-cancer activity with evidence of durable tumor regressions in a subset of human ovarian and breast tumor models at well-tolerated doses. Also promising is in vivo combination data, which show enhanced anti-cancer activity of sovilnesib combined with PARP inhibitor olaparib as compared to olaparib alone.
Findings for one of Volastra’s internally-developed KIF18A inhibitors are shown in a second poster, entitled "Targeting chromosomally unstable tumors with a selective KIF18A inhibitor" (#517). In this, in vivo data shows substantial, dose-dependent inhibition of tumor growth in multiple tumor models. Notably, KIF18A inhibition alters mitotic progression in chromosomally unstable cells but does not impact growth of chromosomally stable or normal cell types, differentiating it from other clinical anti-mitotic agents.
Volastra will advance clinical development of both sovilnesib and the Volastra-developed KIF18A inhibitor VLS-1488 in 2023.